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OBJECTIVE—RIP-B7.1 mice expressing the costimulator mol-
ecule B7.1 (CD80) on pancreatic -cells are a well established
model to characterize preproinsulin-speciﬁc CD8 T-cell re-
sponses and experimental autoimmune diabetes (EAD). Different
immunization strategies could prime preproinsulin-speciﬁc CD8
T-cells in wild-type C57BL/6 (B6) mice, but did not induce
diabetes. We tested whether altering the B7-H1 (PD-L1) coinhi-
bition on pancreatic -cells can reveal a diabetogenic potential of
preproinsulin-speciﬁc CD8 T-cells.
RESEARCH DESIGN AND METHODS—DNA-based immuni-
zation and adoptive T-cell transfers were used to characterize the
induction of preproinsulin-speciﬁc CD8 T-cell responses and
EAD in RIP-B7.1, B6, B7-H1
/, PD-1
/ or bone marrow chi-
meric mice.
RESULTS—Preproinsulin-speciﬁc CD8 T-cells primed in B6
mice revealed their diabetogenic potential after adoptive transfer
into congenic RIP-B7.1 hosts. Furthermore, preproinsulin-spe-
ciﬁc CD8 T-cells primed in anti-B7-H1 antibody-treated B6 mice,
or primed in B7-H1
/ or PD-1
/ mice induced EAD. Immuni-
zation of bone marrow chimeric mice showed that deﬁciency of
either B7-H.1 in pancreatic -cells or of PD-1 in autoreactive CD8
T-cells induced EAD.
CONCLUSIONS—An imbalance between costimulator (B7.1)
and coinhibitor (B7-H1) signals on pancreatic -cells can trigger
pancreatic -cell-destruction by preproinsulin-speciﬁc CD8 T-
cells. Hence, regulation of the susceptibility of the -cells for a
preproinsulin-speciﬁc CD8 T-cell attack can allow or suppress
EAD. Diabetes 59:1966–1973, 2010
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nsulin-producing -cells in the pancreatic islets are
destroyed by an immune attack in autoimmune type
1 diabetes. Type 1 diabetes is triggered by a poorly
deﬁned breakdown in central or peripheral toler-
ance that allows activation of diabetogenic T-cells (1,2).
Preclinical animal models have elucidated some aspects of
the priming and effector phase of a diabetogenic immune
response (3,4). Mice develop diabetes either spontane-
ously in the NOD model (5), or in response to transgene-
encoded “neo-self” antigens selectively expressed in
pancreatic -cells (6–8). These studies indicated that
priming of self-reactive T-cells and -cell susceptibility to
an autoaggressive T-cell attack are distinct steps in the
pathogenesis of the disease.
Costimulating B7/CD28 family molecules provide criti-
cal signals for T-cell activation (9,10). RIP-B7.1 mice
express the B7.1 costimulator in pancreatic -cells under
rat insulin promoter (RIP) control (11). We have shown
that RIP-B7.1 mice develop CD8 T-cell–dependent exper-
imental autoimmune diabetes (EAD) after immunization
with preproinsulin-encoding vectors (12–14). Transgene-
driven B7.1 expression in pancreatic -cells thus makes
them susceptible to T-cell–mediated immune attack.
Coinhibitory signals generated by “programmed
death-1” (PD-1)/“programmed death-ligand-1” (B7-H1 or
PD-L1) interaction downmodulated T-cell responses and
maintain self-tolerance in autoimmune diabetes (15,16).
Inducible or constitutive expression of B7-H1 is found in
many peripheral tissues, including the -cells of the pan-
creatic islets (17,18). Ligation of PD-1 (expressed by
activated T-cells) to B7-H1 (expressed by epitope-present-
ing cells) downmodulates T-cell proliferation and IFN
production (19). Furthermore, B7-H1 interacts speciﬁcally
with the costimulatory B7.1 (CD80) molecule upregulated
by activated T-cells and inhibits their responses (20).
PD-1/B7-H1 interaction facilitates establishment of self-
tolerance, thereby partially controlling diabetes develop-
ment in NOD mice (15,21–23). Selective, transgene-driven
overexpression of B7-H1 by pancreatic -cells can, how-
ever, result in EAD, suggesting operation of a costimula-
tory B7-H1 pathway (24).
We investigated the impact of inhibitory (B7-H1, PD-1)
molecules on the pathogenicity of preproinsulin-speciﬁc
CD8 T-cells. We used RIP-B7.1 mice to characterize the
speciﬁcity and diabetogenic potential of preproinsulin-
speciﬁc CD8 T-cell responses. RIP-B7.1 mice were immu-
nized with preproinsulin-encoding vectors, or used as
hosts for adoptive T-cell transfers. We further analyzed
preproinsulin-speciﬁc CD8 T-cell responses and EAD de-
velopment in C57BL/6 (B6), B7-H1
/ (25), or PD-1
/
knockout mice (26), as well as bone marrow chimeras
(using different donor T-cell and host -cell phenotypes of
B7-H1/PD-1).
RESEARCH DESIGN AND METHODS
H-2
b C57BL/6 (B6) mice were obtained from Janvier (Le Genets-St-Isle;
France). B6.SJL-Ptprc
aPep3
b/BoyJ (CD45.1
 B6) mice (Jackson #002014),
B7-H1
/ mice (25), PD-1
/ mice (26), and RIP-B7.1 mice (11) were bred and
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University (Ulm, Germany). All studies were conducted after Institutional
Board approval in accordance with the Federal German Animal Protection
Law.
Immunization of mice. Mice were immunized intramuscularly into the
tibialis anterior muscle or injected intravenously with 3  10
6 magnetic-
activated cell sorting (MACS)-puriﬁed splenic CD8 T-cells (cat. no. 130-090-
859, Miltenyi Biotech). When indicated, mice were treated with blocking
B7-H1 antibody (clone MIH5; cat. no. 16-5,982-85, eBioscience). Diabetes was
diagnosed if two consecutive blood glucose values exceeded 250 mg/dl, i.e.,
13.8 mmol/l (Disetronic Freestyle, Sulzbach, Germany).
Histology. Histology was performed as described previously (12,14).
Isolation of CD8 T-cells from pancreatic tissue. Pancreata were perfused
in situ with collagenase P (cat. no. 11213865001, Roche) dissolved in 1 mg/ml
Hanks balanced salt solution (HBSS), removed, digested again with collage-
nase P for 8 min at 37°C, and washed twice with cold HBSS supplemented
with 10% FCS. Pancreatic cells were puriﬁed with Histopaque-1077 (cat. no.
10771, Sigma-Aldrich, Germany) by centrifugation for 15 min at 2,400 rpm.
Determination of speciﬁc CD8 T-cell frequencies. Pancreatic cells (10
5/
100 l) were incubated for 14–16 h in UltraCULTURE medium with 5–20
g/ml of the indicated peptides in the presence of brefeldin A (0.5 g/ml) (cat.
no. 15870; Sigma, Taufkirchen, Germany). Cells were harvested, surface
stained with APC-conjugated anti-CD8 antibody (cat no. 17–0081–83, BD
Biosciences, Heidelberg, Germany), ﬁxed with 2% paraformaldehyde, resus-
pended in permeabilization buffer (HBSS, 0.5% BSA, 0.5% saponin, 0.05%
sodium azide), and stained with ﬂuorescein isothiocyanate-conjugated anti-
IFN antibody (cat. no.554411; BD Biosciences, Heidelberg, Germany). Fre-
quencies of IFN
 CD8 T-cells were determined by ﬂow cytometry (FCM).
RESULTS
EAD induced in the RIP-B7.1 model. A single injection
of the pCI/preproinsulin DNA encoding murine preproin-
sulin efﬁciently induced hyperglycemia in RIP-B7.1 mice,
but not in wild-type B6 mice (Fig. 1A) (13,14). PCI/
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FIG. 1. The RIP-B7.1 diabetes model. A: RIP-B7.1 or C57BL/6 (B6) mice were immunized with pCI/preproinsulin ( , n  8) or the noncoding pCI
(▫, n  8). At indicated times after immunization cumulative diabetes incidences (%) were determined. B: RIP-B7.1 mice were immunized with
pCI/preproinsulin DNA. At 3 weeks after immunization, we selected three mice that had developed an early stage of EAD (with blood glucose
levels between 300–440 mg/dl). These mice were injected twice (at days 21 and 23) with 200 g mAb YTS-169 (anti-CD8). The glucose level ( ;
mg/dl) and CD8 T-cell numbers in the blood (▫, CD8 T-cells number of nontreated mice were set for 100%) were determined at indicated time
points after immunization. The injections of pCI/preproinsulin DNA and anti-CD8 mAb are indicated (arrows). C: RIP-B7.1 mice (n  10) were
immunized with pCI/preproinsulin DNA. Pancreatic CD8 T-cells derived from diabetic mice (blood glucose level >400 mg/dl) were pooled and
restimulated ex vivo with a preproinsulin-speciﬁc peptide library (i.e., 10mers with two amino acids offset), and frequencies of IFN
 CD8 T-cells
were determined by ﬂow cytometry. The mean percentage of IFN
 CD8 T-cells in the pancreatic CD8 T-cell population (obtained from two
independent experiments) are shown. D: Pancreatic cells were prepared from pCI/preproinsulin (group 1) or pCI/preproinsulinN110A (group 2)
immunized, diabetic RIP-B7.1 mice, or control pCI-immunized, healthy (group 3) RIP-B7.1 mice and restimulated ex vivo with the K
b/A12–21,
K
b/A12-N21A or K
b/OVA257–264 peptides, and speciﬁc IFN
 CD8 T-cell levels were determined by ﬂow cytometry. The mean percentage of IFN

CD8 T-cells in the pancreatic CD8 T-cell population ( SD) of a representative experiment (n  three mice per group) are shown. pCI/ppins,
pCI/preproinsulin.
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(blood glucose levels of 300–440 mg/dl) were treated 3
weeks after immunization with anti-CD8 antibody (Fig.
1B). This antibody treatment efﬁciently depleted CD8
T-cells within 2–3 days and transiently cured EAD (Fig.
1B). CD8 T-cell levels were restored 3–4 weeks after the
anti-CD8 antibody treatment was discontinued, and EAD
reappeared concomitant with the re-emerging CD8 T-cells
(Fig. 1B). Anti-CD4 antibody treatment did not inhibit
diabetes progression (data not shown). The effector phase
of EAD thus depends on diabetogenic CD8 T-cells.
Characterization of diabetogenic CD8 T-cells. EAD
development in preproinsulin-immunized RIP-B7.1 mice
was accompanied by increasing inﬁltrations of CD8 T-cells
into the pancreatic target tissue (13,14). CD8 T-cells iso-
lated from immunized, diabetic RIP-B7.1 mice speciﬁ-
cally recognized the immunodominant K
b-restricted
A12–21 (i.e., preproinsulin101–110) epitope of preproinsulin
(Fig. 1C) (13,27). Ex vivo stimulation of preproinsulin-
primed, pancreas-inﬁltrating CD8 T-cells with the anti-
genic A12–21 peptide, but not with all other peptides of a
preproinsulin-speciﬁc library, revealed a CD8 T-cell popu-
lation with speciﬁcally inducible IFN expression (Fig.
1C). In the course of EAD, we also found a signiﬁcant
inﬂux of other lymphoid cells (e.g., CD4 T-cells and B
cells) of unknown speciﬁcities into the pancreata (data not
shown) (14). It is under investigation whether these
bystander cells contribute to the diabetogenic immune
response (5,28).
We usually detected 4–8  10
3 CD8 T-cells per pancreas
in preproinsulin-immunized, diabetic RIP-B7.1 mice (with
blood glucose levels of 400 mg/dl). The frequency of
A12–21-speciﬁc IFN
 CD8 T-cells in these pancreatic CD8
T-cell populations was low (0.5–1.5%) (Fig. 1C). We iden-
tiﬁed an epitope variant (A12-N21A) with an alanine (A)
exchange for the COOH-terminal asparagine (N) at posi-
tion A21. This variant facilitated in vitro detection of
primed CD8 T-cells (14). RIP-B7.1 mice immunized with
either pCI/preproinsulin or the pCI/preproinsulinN110A
variant (encoding preproinsulin with the mutant A12-N21A
epitope) developed a similar EAD (data not shown).
Pancreas-inﬁltrating IFN
 CD8 T-cells expanded in vitro
more efﬁciently after stimulation with the mutant A12-N21A
than the A12–21 peptide (Fig. 1D). Similarly, a monospeciﬁc
A12–21-encoding vector induced EAD in RIP-B7.1 mice (14),
but pancreas-inﬁltrating CD8 T-cells preferentially ex-
panded in vitro with the mutant A12-N21A peptide (data not
shown). Hence, the alanine at position A21 of the mutant
epitope apparently modulates the speciﬁc steric structure
of the peptide (29) and improves its major histocompati-
bility complex class I-presentation properties in vitro. We
used the variant epitope to detect preproinsulin-speciﬁc
CD8 T-cell responses.
The effector phase of diabetogenic, preproinsulin-
speciﬁc CD8 T-cell responses is blocked in C57BL/6
(B6) mice. Preproinsulin-speciﬁc immunization efﬁciently
induced EAD in RIP-B7.1 mice, but not in B6 mice (Fig.
1A). However, low numbers of CD8 T-cells were reproduc-
ibly found in the periphery of some (	2%) islets in
immunized B6 mice (Fig. 2A). These CD8 T-cell popula-
tions were not found either in nonimmunized B6 (Fig. 2A)
or nonimmunized RIP-B7.1 mice (13,14), suggesting that
immunization had induced preproinsulin-speciﬁc CD8 T-
cells in B6 mice.
We used adoptive transfer experiments to test
whether functional preproinsulin-speciﬁc CD8 T-cells
are primed in B6 mice. B6 mice were immunized with
pCI/preproinsulinN110A. Their splenic CD8 T-cells isolated
14 days after immunization were adoptively transferred
into RIP-B7.1 mice (30). RIP-B7.1 hosts developed EAD
after transfer with primed (Fig. 2B, group 2), but not with
nonprimed (Fig. 2B, group 1), CD8 T-cells. Preproinsulin-
speciﬁc CD8 T-cells accumulated in the pancreata of
transplanted and diabetic hosts (Fig. 2C, group 2). IFN is
critical for inducing EAD in RIP-B7.1 hosts because adop-
tively transferred CD8 T-cells from immunized IFN
/
mice did not induce EAD (Fig. 2B, group 3). Similarly,
immunization of RIP-B7.1
/IFN
/ mice with preproin-
sulin also did not induce EAD (13).
B7-H1 expression by pancreatic -cells controls the
diabetogenic CD8 T-cell response. We tested whether
EAD can be triggered in preproinsulin-immune B6 mice by
blocking B7-H1-mediated coinhibition. B6 mice injected
with either pCI (Fig. 3A) or pCI/preproinsulinN110A (Fig. 3B
and C) were treated at days 12 and 15 after immuniza-
tion, either with blocking B7-H1 antibody (31) (Fig. 3A
and B) or an isotype control antibody (Fig. 3C). PCI/
preproinsulinN110A-immunized B6 mice rapidly developed
hyperglycemia after injection of the anti-B7-H1, but not
control antibody (Fig. 3B and C). Control mice (injected
with pCI and treated with anti-B7-H1 antibody) did not
develop EAD (Fig. 3A).
Within 6–9 days after anti-B7-H1 antibody injection,
mice developed either severe hyperglycemia (Fig. 3B,
group 1) or moderate and transient hyperglycemia (Fig.
3B, groups 2a/b). Severe disease correlated with an inﬂux
of high levels of A12-N21A-speciﬁc IFN
 CD8 T-cells into
the islets and an almost complete loss of insulin-producing
islet -cells (Fig. 3D and E; group 1). In mice with transient
diabetes, only low numbers of CD8 T-cells were detectable
in the islets during the hyperglycemic stage, and insulin
expression was reduced, but still intact (Fig. 3D and E;
group 2a). After recovery to normoglycemia, CD8 T-cells
were no longer detectable in the islets (Fig. 3D and E;
group 2b). Pancreatic -cells that lose B7-H1 coinhibition
are hence susceptible (at least transiently) to attack by
preproinsulin-speciﬁc CD8 T-cells.
We used B7-H1
/ mice (25) to conﬁrm that EAD
induction by preproinsulin depends on B7-H1. A single
injection of pCI/preproinsulinN110A-induced hyperglycemia
in B7-H1
/ mice. EAD developed in both male and female
B7-H1
/ mice with a median onset of 3–5 weeks after
immunization and a cumulative diabetes incidence of 80%
by week 5 (Fig. 4A, data not shown). B7-H1
/ mice did
not develop spontaneous EAD after injection with the
noncoding pCI vector (Fig. 4A). Using the preproinsulin-
speciﬁc peptide library described above (see Fig. 1C), we
detected only A12–21/A12-N21A-speciﬁc IFN
 CD8 T-cells in
the pancreata of immunized and diabetic B7-H1
/ mice
(data not shown). Thus, CD8 T-cells with this speciﬁcity
play a prominent role in the destructive autoimmune
response in these mice.
We used adoptive cell transfers to exclude that B7-H1-
deﬁciency in CD8 T-cells is critical for EAD development
in B7-H1
/ mice. RIP-B7.1 and B7-H1
/ mice were
immunized with pCI/preproinsulinN110A. We adoptively
transferred 3  10
6 CD8 T-cells (derived from spleens of
early diabetic mice) into RIP-B7.1 hosts (Fig. 4B). RIP-B7.1
hosts reconstituted with primed, RIP-B7.1- or B7-H1
/-
derived CD8 T-cells induced EAD with a similar efﬁcacy
(Fig. 4B). Transfer of nonprimed CD8 T-cells from healthy
RIP-B7.1 or B7-H1
/ donors did not induce EAD (data not
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CD8 T-cells did not alter their diabetogenic potential. In
contrast, transfer of identical RIP-B7.1-derived CD8 T-cell
preparations into B7-H1
/ hosts inefﬁciently induced late
EAD (Fig. 4C). Only 1 of 8 B7-H1
/ hosts developed EAD
at 18 weeks after transfer (Fig. 4C). The efﬁcacy of EAD
could be increased in adoptively transferred B7-H1-
deﬁcient hosts if the stimulatory B7.1 molecule is coex-
pressed in pancreatic -cells of RIP-B7.1
/B7-H1
/
mice (Fig. 4C).
B7-H1/PD-1 coinhibition controls diabetogenic CD8
T-cells. We used PD-1
/ knockout mice (26) to test
whether induction of preproinsulin-speciﬁc EAD depends
on the coinhibitory PD-1/B7-H1 interaction (19). A single
injection of the pCI/preproinsulinN110A (but not of pCI
vector) into PD-1
/ mice induced A12-N21A-speciﬁc IFN

CD8 T-cell responses and EAD (Fig. 4D; data not shown),
suggesting that B7-H1/PD-1 coinhibition is critical to in-
duce EAD in preproinsulin-immune mice. To conﬁrm this,
we generated bone marrow chimeras. To distinguish be-
tween donor- and host-derived T-cells in bone marrow
(BM) chimeras, we used wild-type CD45.1
 B6 mice in this
set of experiments. BM cells from CD45.1
 donor mice
(B7-H1
 PD-1
) were transferred into lethally irradiated,
congenic B7-H1
/ or PD-1
/ (CD45.2
), and BM cells
from B7-H1
/ or PD-1
/ donor mice were transferred
into wild-type CD45.1
 hosts (Table 1). At 6 to 7 weeks
after transplantation, chimeric mice contained 90% of
donor T-cells (data not shown). Chimeric mice were
immunized 7 weeks after transplantation with pCI/
preproinsulinN110A (or control pCI). As is evident from
Table 1, wild-type/B7-H1
/ (group 1) and PD-1
//wild-
type chimeras (group 7), but not wild-type /PD-1
/ (group
3) and B7-H1
//wild-type chimeras (group 5), developed
EAD after immunization with pCI/preproinsulinN110A. EAD
manifestation in groups 1 and 7 correlated with an inﬂux
of A12-N21A-speciﬁc IFN
 CD8 T-cells into the target
tissue (data not shown). Hence, either the selective deﬁ-
ciency of B7-H1 on target cells (group 1) or the deﬁciency
of PD-1 on T-cells (group 7) triggered CD8 T-cell–mediated
EAD. Binding of PD-1 expressed by activated CD8 T-cells
to B7-H1 expressed by pancreatic -cells thus seems to
control the diabetogenic immune response.
DISCUSSION
There is increasing evidence from patients with type 1
diabetes that autoreactive CD8 T-cells speciﬁc for prepro-
insulin are involved in -cell destruction (32–38). We
established mouse models to study the pathogenic cross-
talk between preproinsulin-speciﬁc CD8 T-cells and pre-
proinsulin-expressing -cells. RIP-B7.1 tg and two well
deﬁned (B7-H.1
/, PD-1
/) mouse lines allowed us to
identify critical checkpoints for the control of diabeto-
genic, preproinsulin-speciﬁc CD8 T-cells: 1) the costimu-
lator molecule B7.1 (CD80) expressed on -cells (RIP-B7.1
mice); 2) the coinhibitor B7-H1 (PD-L1) expressed by
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FIG. 2. Priming of preproinsulin-speciﬁc CD8 T-cells in B6 mice. A: C57BL/6 (B6) mice were immunized with pCI/preproinsulinN110A or control
pCI. Twenty-four days after immunization, histology was performed by analyzing pancreatic sections for insulin, CD8, and CD3 T-cells. B and C:
B6 mice remained either untreated (▫, group 1) or were immunized with pCI/preproinsulinN110A ( , group 2). IFN-deﬁcient mice were immunized
with pCI/preproinsulinN110A (E, group 3). B: Fourteen days after injection, CD8 T-cells were isolated from spleens. Next, 3  10
6 splenic CD8
T-cells were transferred intravenously into sublethally (650rad) irradiated RIP-B7.1 hosts, and cumulative diabetes incidences were determined.
C: Pancreatic CD8 T-cells were prepared from healthy hosts (transferred with nonimmune CD8 T-cells, group 1) or diabetic (transferred with
immune CD8 T-cells, group 2) RIP-B7.1 hosts, and restimulated ex vivo with the K
b/A12-N21A or control K
b/OVA257–264 peptide. Speciﬁc IFN
 CD8
T-cell frequencies were determined by ﬂow cytometry. The mean percentage of IFN
 CD8 T-cells in the pancreatic CD8 T-cell population ( SD)
of a representative experiment (n  3 mice per group) is shown. pCI/ppinsN110A, pCI/preproinsulinN110A. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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/ mice); or 3) the coinhibitor PD-1 mole-
cule expressed by CD8 T effector cells (PD-1
/ mice).
Transgene-driven B7.1 (CD80) expression in the pancre-
atic -cells of RIP-B7.1 mice makes them susceptible to
autoreactive CD8 T-cell attack. The nonphysiologic, co-
stimulatory B7.1/CD28 interaction in RIP-B7.1 mice (9,10)
may allow efﬁcient effector function delivery by autoreac-
tive CD8 T-cells. CD28-deﬁcient RIP-B7.1
/CD28
/ mice
did not develop EAD after immunization with preproinsu-
lin (data not shown). There is thus strong evidence that the
interaction of B7.1 on the surface of -cells with the
costimulator molecule CD28 on T-cells is an essential
component of T-cell–mediated EAD in RIP-B7.1 mice.
Preproinsulin-speciﬁc immunization induced EAD in al-
most all RIP-B7.1 mice with a strikingly similar time
course and histopathology. Expression of B7.1 in islet
-cells facilitated diabetes development by adoptively
transferred preproinsulin-speciﬁc CD8 T-cells (Fig. 4C)
(30). The RIP-B7.1 diabetes model is thus well suited to
study distinct events in the priming and effector phase of
preproinsulin-speciﬁc CD8 T-cells. For example, we previ-
ously showed that expression and processing of preproin-
sulin antigens in the endoplasmic reticulum favor priming
of autoreactive CD8 T-cells (14). Thus, direct loading of
the A12–21 epitope on newly synthesized K
b-molecules in
the endoplasmic reticulum may be an essential step for
enabling presentation of this epitope (14). We currently
establish a HLA-A*0201
/RIP-B7.1 mouse model to deﬁne
the diabetogenic potential of HLA-A*0201-restricted pre-
proinsulin epitopes associated with human type 1 diabetes
(35–37). Furthermore, RIP-B7.1 mice are a useful tool to
identify novel -cell antigens that are targets for CD8
T-cell–triggered diabetes (4).
We consider the key observation of this report to be the
de novo induction of preproinsulin-speciﬁc CD8 T-cells
(and EAD) in mice and their control by B7-H1/PD-1
interaction. It has been shown that PD-1 and its ligands,
B7-H1 (PD-L1) and PD-L2, deliver inhibitory signals that
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FIG. 3. Blocking B7–H1 coinhibition induced EAD in pCI/preproinsulinN110A-immunized B6 mice. B6 mice were immunized with pCI (A)o r
pCI/preproinsulinN110A (B and C). At days 12 and 15 after immunization, mice were injected with blocking B7–H1 antibody (A and B) or control
antibody (C), and blood glucose levels were followed up during the experiment. B,D, and E: Preproinsulin-immune and B7–H1 antibody-treated
B6 mice developed either a severe hyperglycemia (with blood glucose levels >550 mg/dl, group 1) or a moderate hyperglycemia (with blood
glucose levels of 250–360 mg/dl, group 2a) which subsequently returned to normoglycemia (with blood glucose levels of <200 mg/dl, group 2b).
Representative mice in groups 1, 2a, and 2b were analyzed histologically for insulin expression and CD8 T-cell inﬂux (D), or were analyzed for
preproinsulin-speciﬁc CD8 T-cells (E). Pancreatic CD8 T-cells were restimulated ex vivo with the K
b/A12-N21A or control K
b/OVA257–264 peptide,
and IFN
 CD8 T-cell levels were determined by ﬂow cytometry (E). pCI/ppinsN110A, pCI/preproinsulinN110A. (A high-quality digital representa-
tion of this ﬁgure is available in the online issue.)
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and immunopathology (19,39). B7-H1 (PD-L1) is expressed
on antigen-presenting cells as well as effector CD8 T-cells,
whereas PD-1 is expressed on T-cells. Using bone marrow
chimeric mice, we conﬁrmed that the deﬁciency of B7-H1
on target cells or PD-1 on T-cells was essential to trigger
preproinsulin-speciﬁc, CD8 T-cell–mediated EAD by DNA-
based immunization (Table 1). Binding of PD-1 on acti-
vated T-cells to B7-H1 expressed by pancreatic -cells may
hence downmodulate the diabetogenic potential of prepro-
insulin-speciﬁc CD8 T-cells. We further showed that B7-
H1-deﬁciency in preproinsulin-speciﬁc CD8 T-cells did not
alter their diabetogenic potential (Fig. 4B). B7-H1
/ mice
inefﬁciently developed EAD after adoptive transfer of
preproinsulin-speciﬁc CD8 T-cells, but coexpression of the
stimulatory B7.1 molecule in B7-H1-deﬁcient pancreatic
-cells (RIP-B7.1
/B7-H1
/ mice) signiﬁcantly acceler-
ated disease induction (Fig. 4C). Transgene-driven B7.1
costimulation in pancreatic -cells was thus more potent
than the loss of B7-H1 coinhibition in promoting the
pathogenic immune response of adoptively transferred
preproinsulin-speciﬁc CD8 T-cells. In contrast, immuniza-
tion of B7-H1
/ and RIP-B7.1 mice with preproinsulin-
encoding DNA induced EAD with similar efﬁcacies and
kinetics (see Figs. 1A,4 A). We assume that additional
factors (e.g., professional antigen-presenting dendritic
cells or cells from the innate immune system) (40) are
triggered by DNA-based immunization that facilitate ex-
pansion of preproinsulin-speciﬁc CD8 T-cells and/or main-
tain their diabetogenic potential in B7-H1
/ mice.
The B6 diabetes model described in this study is attrac-
tive to characterize distinct events in the regulation of
-cell susceptibility to manifest or control preproinsulin-
speciﬁc, CD8 T-cell–mediated EAD. B6 is not a privileged
strain for type 1 diabetes studies, but it was unexpectedly
easy to prime preproinsulin-speciﬁc CD8 T-cells in male
and female B6 mice. CD8 T-cells revealed their diabeto-
genic potential after adoptive transfer into congenic RIP-
B7.1 hosts or after conditioning the pancreatic target
tissue by antibody-mediated blockage of B7-H1 coinhibi-
ton (Figs. 2 and 3). Preproinsulin-speciﬁc CD8 T-cells in
immunized B6 mice thus have a diabetogenic potential,
but pancreatic -cells are protected from immune attack
by these cells. Similarly, in the lymphocytic choriomenin-
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FIG. 4. Preproinsulin-speciﬁc EAD development in B7–H1
/ and PD-1
/ mice. A: B7–H1
/ mice were immunized with pCI/preproinsulinN110A (F,
n  5), or the noncoding pCI (E, n  8), and cumulative diabetes incidences (%) were determined. B: RIP-B7.1 ( ) and B7–H1
/ (F) mice were
immunized with pCI/preproinsulinN110A. Spleens were removed from early diabetic mice and 3  10
6 CD8 T-cells were transferred intravenously
into sublethally irradiated RIP-B7.1 hosts, and cumulative diabetes incidences (%) were determined. C: In addition, spleens were removed from
early diabetic RIP-B7.1 mice, and 3  10
6 CD8 T-cells were transferred intravenously into sublethally irradiated B7–H1
/ (▫, n  8) or
RIP-B7.1
/B7–H1
/ (‚, n  4) hosts. D: PD-1
/ mice were immunized with pCI/preproinsulinN110A (F, n  12), or the noncoding pCI (E, n  12),
and cumulative diabetes incidences (%) were determined. pCI/ppinsN110A, pCI/preproinsulinN110A.
TABLE 1
Preproinsulin-speciﬁc EAD induction in bone marrow chimeras
Group Bone marrow chimera Donor Host Immunization EAD
1 wt/B7-H1
/ CD45.1
 wt B7-H1
/ pCI/ppinsN110A 4/4
2 wt/B7-H1
/ CD45.1
 wt B7-H1
/ pCI 0/3
3 wt/PD-1
/ CD45.1
 wt PD-1
/ pCI/ppinsN110A 0/4
4 wt/PD-1
/ CD45.1
 wt PD-1
/ pCI 0/3
5 B7-H1
//wt B7-H1
/ CD45.1
 wt pCI/ppinsN110A 0/4
6 B7-H1
//wt B7-H1
/ CD45.1
 wt pCI 0/2
7 PD-1
//wt PD1
/ CD45.1
 wt pCI/ppinsN110A 2/4
8 PD-1
//wt PD1
/ CD45.1
 wt pCI 0/4
Bone marrow chimeras were generated by injecting wild-type CD45.1
 bone marrow cells intravenously into lethally irradiated (950 rad)
B7-H1
/ (CD45.2
) or PD-1
/ (CD45.2
) hosts, or by injecting B7-H1
/ or PD-1
/ bone marrow cells into wild-type CD45.1
 hosts. Mice
were injected 7 weeks after transplantation with either the pCI/ppinsN110A, or control pCI plasmid DNA. Blood glucose levels were
determined, and the number of diabetic mice per group is indicated. wt, wild-type; ppinsN110A, preproinsulinN110A.
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must be exposed to stimulatory signals from the innate
immune system to become susceptible to the destructive
CD8 T-cell attack (8). The B6 model is a good example for
translational medicine since our data illustrated the cen-
tral role of the -cell as a gatekeeper in the preproinsulin-
speciﬁc insulitic process. Beta cells per se prevent the
deleterious cross-talk with preproinsulin-speciﬁc CD8 T-
cells. Changes in the -cell milieu—e.g., by antibody
treatment (Fig. 3), by interferon (8), or by viral infections
(41)—can favor the susceptibiliy of -cells for the CD8
T-cell–mediated immune attack. Further manipulations of
the pancreatic -cells or distinct arms of the immune
system by speciﬁc drugs (42) or by using different mouse
strains with defects in speciﬁc cell types or immune-
mediators may deﬁne conditions that inactivate (tolerize/
anergize) autoreactive CD8 T-cells. “Translation” of these
approaches to human type 1 diabetes (3,41–43) could be
helpful to design prophylactic vaccines.
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